Drug switching policy for atopic dermatitis fails to address
By Whang, byung-woo | translator Hong, Ji Yeon
24.11.20 05:45:01
가나다라
0
The SADA states that the current draft of the revision may impose restrictions on the treatment settings used for atopic dermatitis
HIRA's draft for revision places restrictions on drug switching within the same class of drugs
The Embassy of Denmark, "We will consider suggesting various approaches to the MOHW, in addition to atopic dermatitis"
A discussion has been advancing to allow drug switching between a biological agent and a JAK inhibitor for treating atopic dermatitis (hereafter referred to as atopy), and there have been further suggestions for the revision.
The Health Insurance Review and Assessment Service (HIRA) has already established reimbursement criteria, but concerns have been raised about potential challenges in the effective use of the drug, including drug switching between drugs of the same class.
▲(clockwise from top left) Product photos of Dupixent, Rinvoq, Olumiant, Adtralza, and Cibinqo
The Embassy of Denmark in Korea met with the Severe Atopic Dermatitis Association (SADA) to discuss potential improvements to atopy treatment settings and systems.
The HIRA has exchanged opinio
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)